Raoul Emeric Guetiya Wadoum

Dr. Raoul Emeric Guetiya Wadoum


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
BDBoubacar Diallo
Boubacar Diallo
DSDaouda Sissoko
Daouda Sissoko
NLNicholas J. Loman
Nicholas J. Loman
HBHadja Aïssatou Bah
Hadja Aïssatou Bah
HBHawa Bah
Hawa Bah
SDSophie Duraffour
Sophie Duraffour
We report on an Ebola virus disease (EVD) survivor who showed Ebola virus in seminal fluid 531 days after onset of disease. The persisting virus was sexually transmitted in February 2016, about 470 days after onset of symptoms, and caused a new cluster of EVD in Guinea and Liberia.

1 January 2016 in Virus Evolution
Verified
Journal Article
Open access
AAArmando Arias
Armando Arias
SWSimon J. Watson
Simon J. Watson
DADanny Asogun
Danny Asogun
ETEkaete Alice Tobin
Ekaete Alice Tobin
JLJia Lu
Jia Lu
MCMatthew Cotten
Matthew Cotten
To end the largest known outbreak of Ebola virus disease (EVD) in West Africa and to prevent new transmissions, rapid epidemiological tracing of cases and contacts was required. The ability to quickly identify unknown sources and chains of transmission is key to ending the EVD epidemic and of even greater importance in the context of recent reports of Ebola virus (EBOV) persistence in survivors. Phylogenetic analysis of complete EBOV genomes can provide important information on the source of any new infection. A local deep sequencing facility was established at the Mateneh Ebola Treatment Centre in central Sierra Leone. The facility included all wetlab and computational resources to rapidly process EBOV diagnostic samples into full genome sequences. We produced 554 EBOV genomes from EVD cases across Sierra Leone. These genomes provided a detailed description of EBOV evolution and facilitated phylogenetic tracking of new EVD cases. Importantly, we show that linked genomic and epidemiological data can not only support contact tracing but also identify unconventional transmission chains involving body fluids, including semen. Rapid EBOV genome sequencing, when linked to epidemiological information and a comprehensive database of virus sequences across the outbreak, provided a powerful tool for public health epidemic control efforts.

24 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
BABrian R. Amman
Brian R. Amman
BBBrian H. Bird
Brian H. Bird
IBIbrahim A. Bakarr
Ibrahim A. Bakarr
JBJames Bangura
James Bangura
ASAmy J. Schuh
Amy J. Schuh
ALAIAH LEBBIE
AIAH LEBBIE
Marburg virus (MARV) causes sporadic outbreaks of severe Marburg virus disease (MVD). Most MVD outbreaks originated in East Africa and field studies in East Africa, South Africa, Zambia, and Gabon identified the Egyptian rousette bat (ERB; Rousettus aegyptiacus) as a natural reservoir. However, the largest recorded MVD outbreak with the highest case–fatality ratio happened in 2005 in Angola, where direct spillover from bats was not shown. Here, collaborative studies by the Centers for Disease Control and Prevention, Njala University, University of California, Davis USAID-PREDICT, and the University of Makeni identify MARV circulating in ERBs in Sierra Leone. PCR, antibody and virus isolation data from 1755 bats of 42 species shows active MARV infection in approximately 2.5% of ERBs. Phylogenetic analysis identifies MARVs that are similar to the Angola strain. These results provide evidence of MARV circulation in West Africa and demonstrate the value of pathogen surveillance to identify previously undetected threats.

1 June 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
JGJudith R Glynn
Judith R Glynn
HBHilary Bower
Hilary Bower
SJSembia Johnson
Sembia Johnson
CHCatherine F Houlihan
Catherine F Houlihan
MCMontesano Carla
Montesano Carla
RTRichard S Tedder
Richard S Tedder
The frequency of asymptomatic infection with Ebola virus is unclear: previous estimates vary and there is no standard test. Asymptomatic infection with Ebola virus could contribute to population immunity, reducing spread. If people with asymptomatic infection are infectious it could explain re-emergences of Ebola virus disease (EVD) without known contact. We validated a new oral fluid anti-glycoprotein IgG capture assay among survivors from Kerry Town Ebola Treatment Centre and controls from communities unaffected by EVD in Sierra Leone. We then assessed the seroprevalence of antibodies to Ebola virus in a cross-sectional study of household contacts of the survivors. All household members were interviewed. Two reactive tests were required for a positive result, with a third test to resolve any discrepancies. The assay had a specificity of 100% (95% CI 98·9-100; 339 of 339 controls tested negative) and sensitivity of 95·9% (89·8-98·9; 93 of 97 PCR-confirmed survivors tested positive). Of household contacts not diagnosed with EVD, 47·6% (229 of 481) had high level exposure (direct contact with a corpse, body fluids, or a case with diarrhoea, vomiting, or bleeding). Among the contacts, 12·0% (95% CI 6·1-20·4; 11 of 92) with symptoms at the time other household members had EVD, and 2·6% (1·2-4·7; 10 of 388) with no symptoms tested positive. Among asymptomatic contacts, seropositivity was weakly correlated with exposure level. This new highly specific and sensitive assay showed asymptomatic infection with Ebola virus was uncommon despite high exposure. The low prevalence suggests asymptomatic infection contributes little to herd immunity in Ebola, and even if infectious, would account for few transmissions. Wellcome Trust ERAES Programme, Save the Children.

29 June 2016 in British Poultry Science
Verified
Journal Article
Closed access
RWRaoul Emeric Guetiya Wadoum
Raoul Emeric Guetiya Wadoum
NZN. F. Zambou
N. F. Zambou
FAF. F. Anyangwe
F. F. Anyangwe
JNJ. R. Njimou
J. R. Njimou
MCMaria Magdalena Coman
Maria Magdalena Coman
VCV. Colizzi
V. Colizzi
The types and methods of use of antibiotics in poultry farms in Cameroon, residual levels and potential microbial resistance were determined.A questionnaire-based survey identified the different an...

1 December 2021 in Risk Management and Healthcare Policy
Verified
Journal Article
Open access
PDF file
RWRaoul Emeric Guetiya Wadoum
Raoul Emeric Guetiya Wadoum
SSStephen Sevalie
Stephen Sevalie
AMAntonella Minutolo
Antonella Minutolo
ACAndrew Clarke
Andrew Clarke
GRGianluca Russo
Gianluca Russo
CMCarla Montesano
Carla Montesano
The Ebola virus disease, formerly known as Ebola hemorrhagic fever, is a severe and often fatal zoonosis in humans. The 2013– 2016 West African Ebola outbreak had distinctive characteristics, and it was the largest and most complex epidemic since the virus discovery in 1976. Although the 2018– 2020 Ebola outbreak in the Democratic Republic of the Congo had many similarities, there were additional challenges due to the presence of armed rebel groups at the epicenters of the epidemic. Despite these challenges, the extraordinary commitment of the World Health Organization (WHO) regional office for Africa, in collaboration with Africa Union (AU) member states through the Africa Centres for Disease Control and Prevention (Africa CDC), and WHO’s prompt declaration of a Public Health Emergency of International Concern (PHEIC) shepherded an effective coordinated response to contain the epidemic. Learning from previous Ebola virus epidemics and the current Coronavirus disease 2019 (COVID-19) pandemic, the AU member states should strengthen inter-state coordination towards the development and implementation of a preparedness and readiness plan which will enable the continent to build and sustain resilient capacities to prevent, detect, and respond to future outbreaks following the International Health Regulations (IHR).